{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:50Z","timestamp":1791219410064,"version":"4.1.0"},"reference-count":6,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"36","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,12,20]]},"abstract":"<jats:p>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.<\/jats:p>\n                  <jats:p>The phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles plus platinum-based chemotherapy, with or without bevacizumab, showed statistically significant survival benefits with the addition of pembrolizumab for patients with persistent, recurrent, or metastatic cervical cancer (primary data cutoff: May 3, 2021). This article reports the protocol-specified final overall survival (OS) results tested in the PD-L1 combined positive score (CPS) \u22651, all-comer, and CPS \u226510 populations. At the final data cutoff (October 3, 2022), the median study follow-up duration was 39.1 months (range, 32.1-46.5 months). In the PD-L1 CPS \u22651 (N = 548), all-comer (N = 617), and CPS \u226510 (N = 317) populations, median OS with pembrolizumab\u2013chemotherapy versus placebo\u2013chemotherapy was 28.6 months versus 16.5 months (hazard ratio [HR] for death, 0.60 [95% CI, 0.49 to 0.74]), 26.4 months versus 16.8 months (HR, 0.63 [95% CI, 0.52 to 0.77]), and 29.6 months versus 17.4 months (HR, 0.58 [95% CI, 0.44 to 0.78]), respectively. The incidence of grade \u22653 adverse events was 82.4% with pembrolizumab\u2013chemotherapy and 75.4% with placebo\u2013chemotherapy. These results show that pembrolizumab plus chemotherapy, with or without bevacizumab, continued to provide clinically meaningful improvements in OS for patients with persistent, recurrent, or metastatic cervical cancer.<\/jats:p>","DOI":"10.1200\/jco.23.00914","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T15:59:13Z","timestamp":1698854353000},"page":"5505-5511","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":266,"title":["First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03635567","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J.","family":"Monk","sequence":"first","affiliation":[{"name":"HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-715X","authenticated-orcid":false,"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Universit\u00e0 degli Studi di Milano Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-7000","authenticated-orcid":false,"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[{"name":"Obstetrics & Gynecology, University of California, Irvine, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coraline","family":"Dubot","sequence":"additional","affiliation":[{"name":"Oncologie M\u00e9dicale, Institut Curie Saint Cloud, and GINECO, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Valeria","family":"Caceres","sequence":"additional","affiliation":[{"name":"Medical Oncology, Instituto de Oncologia Angel H. Roffo, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-7001","authenticated-orcid":false,"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-8124","authenticated-orcid":false,"given":"Pamela","family":"Salman","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncovida Cancer Center, Providencia, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ya\u00f1ez","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universidad de la Frontera, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3550-9993","authenticated-orcid":false,"given":"Mahmut","family":"G\u00fcm\u00fc\u015f","sequence":"additional","affiliation":[{"name":"Medical Oncology, Istanbul Medeniyet University Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-0800","authenticated-orcid":false,"given":"Mivael","family":"Olivera Hurtado de Mendoza","sequence":"additional","affiliation":[{"name":"Medical Oncology, Instituto Nacional de Enfermedades Neopl\u00e1sicas, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Samou\u00eblian","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Centre de Recherche de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Universit\u00e9 de Montr\u00e9al, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Castonguay","sequence":"additional","affiliation":[{"name":"Medical Oncology, Centre Hospitalier Universitaire de Qu\u00e9bec, Universit\u00e9 Laval, Quebec City, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Arkhipov","sequence":"additional","affiliation":[{"name":"Oncology and Chemical Therapy, Medical Rehabilitation Center under the Ministry of Health of Russian Federation, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cumhur","family":"Tekin","sequence":"additional","affiliation":[{"name":"Oncology, Merck & Co, Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-7440","authenticated-orcid":false,"given":"Kan","family":"Li","sequence":"additional","affiliation":[{"name":"Oncology, Merck & Co, Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Keefe","sequence":"additional","affiliation":[{"name":"Oncology, Merck & Co, Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Gynaecology Oncology Unit, Fondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the KEYNOTE-826 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5471"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8909"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1309748"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.23.00914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T18:00:52Z","timestamp":1702663252000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.23.00914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":6,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2023,12,20]]}},"alternative-id":["10.1200\/JCO.23.00914"],"URL":"https:\/\/doi.org\/10.1200\/jco.23.00914","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"2023-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}